Danish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases.
Pfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology.
Paris-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
The charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer.
Noema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline.
The Supervisory Board of Bayer AG has appointed Roche Pharmaceuticals CEO Bill Anderson (56) as new Chairman of the Management Board of Bayer AG with effect from 1 June 2023.
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Antiverse Ltd.’s AI identified eight antibodies with therapeutic potential for humans and raised €2.8m in funding for continued in-house development.
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
There is increasing interest in delivering a range of drugs via inhalation because of the benefits it can offer patients. Lonza’s Kim Shepard looks at the advantages of pulmonary delivery, and the prospect for inhaled biologics.